Huntsman Cancer Institute Joins National Clinical Trial Targeting AML

News   Mar 19, 2018 | Original story from the Huntsman Cancer Institute (HCI)

 
Huntsman Cancer Institute Joins National Clinical Trial Targeting AML

These are the HCI physicians from left to right: Paul Shami, M.D., Tibor Kovacsovics, M.D. and Michael Deininger, M.D., Ph.D. Credit: Jonathan Martinez, Huntsman Cancer Institute

 
 
 

RELATED ARTICLES

Sweet Spot of Activity in Immune System Key to Fighting Cancer

News

Scientists have shown how stimulating a specific location on the surface of immune cells can be targeted with antibodies to help in their fight against cancer.

READ MORE

Compound Offers Pain-relief of Opioids Without Addictive Properties

News

Researchers have engineered a new compound that animal tests suggest could offer the pain-relieving properties of opioids such as morphine and oxycodone without the risk of addiction.

READ MORE

E. Coli’s Internal Bomb Offers Chink In Armour

News

Bacteria's internal bomb, the so-called toxin-antitoxin (TA) system that is part of the normal bacterial makeup, may be triggered to make bacteria turn on themselves, providing a valuable target for novel antimicrobial approaches in drug design.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE